PI-PLCβ1 gene copy number alterations in breast cancer

Oncology Reports

Volumn 27, Issue 2, 2012, Pages 403-408

  Molinari, Chiara ^a   Medri, Laura ^b   Follo, Matilde Y ^c   Piazzi, Manuela ^c   Mariani, Giulia Adalgisa ^c   Calistri, Daniele ^a   Cocco, Lucio ^c  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Breast cancer; Chromosome 20; Fluorescence in situ hybridization; Mitotic activity index; PI PLC 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE C BETA1; PHOSPHOLIPASE C BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; INVASIVE DUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS INDEX; PHENOTYPE; PHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE C BETA1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PHENOTYPE; PHOSPHOLIPASE C BETA; RNA, MESSENGER;

EID: 84855744293     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1529     Document Type: Article

References (36)

1. Wilson CM, Tobin S and Young RC: The exploding worldwide cancer burden: the impact of cancer on women. Int J Gynecol Cancer 14: 1-11, 2004. (Pubitemid 38280618)
2. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA and Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med (Berl) 75: 429-439, 1997. (Pubitemid 27297013)
3. Van de Vijver MJ and Peterse H: The diagnosis and management of pre-invasive breast disease: pathological diagnosis - problems with existing classifications. Breast Cancer Res 5: 269, 2003.
4. Allred DC, Hilsenbeck SG and Mohsin SK: Biological features of human premalignant breast disease. In: Diseases of the Breast. Harris JR, Lippman ME, Morrow M and Osborne CK (eds). 3rd edition. Lippincott Williams and Wilkins, Philadelphia, pp507-520, 2004.
5. Allred DC, Wu Y, Mao S, et al: Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14: 370-378, 2008. (Pubitemid 351226103)
6. Deranieh RM and Greenberg ML: Cellular consequences of inositol depletion. Biochem Soc Trans 37: 1099-1103, 2009.
7. Ramazzotti G, Faenza I, Fiume R, et al: The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol 226: 14-20, 2011.
8. Follo MY, Mongiorgi S, Finelli C, et al: Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem 109: 1065-1071, 2010.
9. Peruzzi D, Aluigi M, Manzoli L, et al: Molecular characterization of the human PLC beta1 gene. Biochim Biophys Acta 1584: 46-54, 2002.
10. Peruzzi D, Calabrese G, Faenza I, et al: Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C β1. Biochim Biophys Acta 1484: 175-182, 2000. (Pubitemid 30175967)
11. Martelli AM, Billi AM, Manzoli L, et al: Insulin selectively stimulates nuclear phosphoinositide-specific phospholipase C (PI-PLC) beta1 activity through a mitogen-activated protein (MAP) kinase-dependent serine phosphorylation. FEBS Lett 486: 230-236, 2000.
12. Xu A, Suh PG, Marmy-Conus N, et al: Phosphorylation of nuclear phospholipase C beta1 by extracellular signal-regulated kinase mediates the mitogenic action of insulin-like growth factor I. Mol Cell Biol 21: 2981-2990, 2001. (Pubitemid 32298366)
13. Faenza I, Billi AM, Follo MY, et al: Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Anticancer Res 25: 2039-2041, 2005. (Pubitemid 40904601)
14. Silvestrini R: Relevance of DNA-ploidy as a prognostic instrument for solid tumors. Ann Oncol 11: 259-261, 2000.
15. Albertson DG: Gene amplification in cancer. Trends Genet 22: 447-455, 2006.
16. Reis-Filho JS and Lakhani SR: The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 5: 313-319, 2003.
17. James LA, Mitchell EL, Menasce L and Varley JM: Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 14: 1059-1065, 1997.
18. Letessier A, Sircoulomb F, Ginestier C, et al: Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6: 245, 2006.
19. Ginestier C, Cervera N, Finetti P, et al: Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12: 4533-4544, 2006. (Pubitemid 44297802)
20. Nakopoulou L, Tsirmpa I, Giannopoulou I, Trafalis D, Katsarou S and Davaris P: Aneuploidy of chromosome 20 in invasive breast cancer correlates with poor outcome. Cancer Genet Cytogenet 134: 127-132, 2002. (Pubitemid 34553456)
21. Hodgson JG, Chin K, Collins C and Gray JW: Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 78: 337-345, 2003. (Pubitemid 36543213)
22. The World Health Organization: Histological Typing of Breast Tumours. World Health Organization, Geneva, 1981.
23. Tavassoli FA and Devilee P (eds): World Health Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, 2003.
24. Holland R, Peterse JL, Millis RR, et al: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180, 1994.
25. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
26. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
27. Medri L, Volpi A, Nanni O, et al: Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol 16: 1067-1075, 2003. (Pubitemid 37414200)
28. Carles J, Lloreta J, Salido M, et al: Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 10: 4742-4745, 2004.
29. Montironi R and Mazzucchelli R: HER-2 expression and gene amplification in high-grade PIN and prostate cancer. Arch Ital Urol Androl 78: 135-139, 2006. (Pubitemid 46113688)
30. Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG and Wells A: A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res 5: 2251-2260, 1999. (Pubitemid 29399285)
31. Leung DW, Tompkins C, Brewer J, et al: Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells. Mol Cancer 3: 15, 2004.
32. Bertagnolo V, Benedusi M, Querzoli P, et al: PLC-β2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. Int J Oncol 28: 863-872, 2006.
33. Bertagnolo V, Benedusi M, Brugnoli F, et all: Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis 28: 1638-1645, 2007.
34. Rebecchi MJ, Raghubir A, Scarlata S, Hartenstine MJ, Brown T and Stallings JD: Expression and function of phospholipase C in breast carcinoma. Adv Enzyme Regul 49: 59-73, 2009.
35. Faenza I, Matteucci A, Manzoli L, et al: A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem 275: 30520-30524, 2000.
36. Sorlie T, Wang Y, Xiao C, et al: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7: 127, 2006.